Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib leads to higher overall survival (absolute effect size estimates based on survival… compared with nivolumab + ipilimumab (targeted agent versus combinations of… (high certainty).
1 finding from 1 review
- HR 1.52 [1.23, 1.89]1 study · 847 participantsHigh